More than Hormones? Metabolic Effects of Twelve-Week Probiotic Supplementation in Women with Polycystic Ovary Syndrome: A Secondary Analysis of a Randomized Double-Blind Placebo-Controlled Study
Abstract
Background: Polycystic ovary syndrome (PCOS) is frequently associated with insulin resistance and dyslipidemia. Evidence regarding the metabolic effects of probiotics in PCOS remains inconsistent. This secondary analysis evaluated whether multispecies probiotic supplementation influenced glucose homeostasis, insulin resistance, and the lipid profile in women with PCOS. Methods: Data were derived from a 12-week randomized, double-blind, placebo-controlled study in which 50 women with PCOS were assigned to receive either a nine-strain probiotic (1.0 × 109 CFU/day) or placebo. Fasting and 120 min glucose and insulin concentrations, HOMA-IR, total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides were assessed at baseline and follow-up. Treatment effects were evaluated using analysis of covariance adjusted for baseline values. The main analysis was based on participants with available follow-up data, and an intention-to-treat sensitivity analysis including all 50 randomized participants was performed using multiple imputation for missing follow-up measurements. Results: Forty-three participants were included in the complete-case analysis (probiotic, n = 19; placebo, n = 24); seven did not complete follow-up (six in the probiotic group, one in the placebo group). No statistically significant between-group differences were detected for glucose homeostasis, HOMA-IR, or lipid profile. The intention-to-treat sensitivity analysis yielded findings consistent with the…
How strong is the evidence?
Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 50 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.